YB4P Stock Chart & Stats
€4.66
-€0.11(-2.27%)
At close: 4:00 PM EDT
€4.66
-€0.11(-2.27%)
Day’s Range― - ―
52-Week Range€2.74 - €5.90
Previous CloseN/A
Volume0.00
Average Volume (3M)102.00
Market Cap
€989.37M
Enterprise Value€1.42K
Total Cash (Recent Filing)€173.03M
Total Debt (Recent Filing)€30.11M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Nov 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding205,460,020
10 Day Avg. Volume100
30 Day Avg. Volume102
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.57Price Target Upside105.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.48
Revenue Forecast (FY)€2.26M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityLow leverage and positive equity provide a financial cushion relative to debt, giving Savara more flexibility to fund development and manage obligations while pursuing regulatory milestones.
Focused Rare-Disease PipelineA focused program in a rare respiratory disease can concentrate resources, support specialized clinical expertise, and create potential differentiation if molgramostim demonstrates meaningful efficacy and gains approval.
Expanded Financing FlexibilityThe expanded share authorization increases the company’s ability to raise capital and fund clinical development, potentially reducing financing constraints as it advances toward commercialization.
Bears Say
No Commercial RevenueWithout approved products or sales, Savara has no operating revenue base to support development costs, leaving its long-term progress dependent on clinical success and continued external financing.
Widening Losses And Cash BurnDeepening losses and substantial recurring cash burn indicate that operations are not self-funding, increasing the need for capital raises and heightening execution risk during clinical development.
Dilution And Leadership Transition RiskA larger equity pool and expanded share authorization can dilute existing holders, while the finance leadership transition may temporarily increase execution and financial-management uncertainty.
Savara News
YB4P FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was €2.74 and its highest was €5.90 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is €989.37M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Nov 05, 2026 which is in 68 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Aug 11, 2026. The company reported -€0.139 earnings per share for the quarter, missing the consensus estimate of -€0.122 by -€0.016.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.13.
How many shares outstanding does Savara have?
Savara has 205,460,020 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -€0.139 in its last earnings report, missing expectations of -€0.122. Following the earnings report the stock price went down -2.725%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in DE:YB4P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.57 (105.34% Upside)
€9.57 (105.34% Upside)
Blogger Sentiment
Bullish
DE:YB4P Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €1.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.33%
Trailing 12-Months
Company Description
Savara
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
YB4P Stock 12 Month Forecast
Average Price Target
€9.57
▲(105.34% Upside)